Glenn C. Rice
Gründer bei Pacific Biopharma Group
Profil
Glenn C.
Rice is the founder of Bridge Pharmaceuticals, Inc. (2004), Critical Path Institute (2005), Pacific Biopharma Group (2007), and Convergence Pharmaceuticals, Inc. (1999).
At Convergence Pharmaceuticals, Inc., he held the title of President & Chief Executive Officer.
Dr. Rice is also the founder of EmergingMed.com, Inc. Dr. Rice's former jobs include Director at CTI BioPharma Corp.
(1993-1998), Director & Vice President-Research at ILEX Oncology, Inc. (1999-2002), Head-Discovery Laboratory at Genentech, Inc. (1987-1993), Vice President-Biosciences at SRI International (2002-2004), Vice President-Research at Cytokine Networks (1998-1999), Chief Executive Officer at Pacific Biopharma Group (2009), and President & Chief Operating Officer at Pharmacyclics LLC (2008-2010).
Aktive Positionen von Glenn C. Rice
Unternehmen | Position | Beginn |
---|---|---|
Pacific Biopharma Group | Gründer | 03.12.2009 |
Bridge Pharmaceuticals, Inc.
Bridge Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Bridge Laboratories is a preclinical contract research organization (CRO) that provides US-level regulatory-compliant drug development services globally. Bridge is known for its extensive work in toxicology, including vaccines, and safety pharmacology. The company's AAALAC-accredited facility in China was among the first labs to perform GLP studies for clients worldwide. Bridge Laboratories gives drug development clients-biotech/pharmaceutical firms, government agencies and virtual companies with strong outsourcing needs-a CRO choice that can dramatically improve the speed and cost-effectiveness of their drug development research programs. | Gründer | 01.01.2004 |
Ehemalige bekannte Positionen von Glenn C. Rice
Unternehmen | Position | Ende |
---|---|---|
PHARMACYCLICS, INC. | Präsident | 15.02.2010 |
Pacific Biopharma Group | Präsident | 01.01.2009 |
SRI International
SRI International Miscellaneous Commercial ServicesCommercial Services SRI International provides contract research and development services. It is an independent, nonprofit research institute conducting client-sponsored research and development for government agencies, commercial businesses, foundations, and other organizations. The company was founded in 1946 and is headquartered in Menlo Park, CA. | Corporate Officer/Principal | 01.01.2004 |
ILEX Oncology, Inc.
ILEX Oncology, Inc. BiotechnologyHealth Technology ILEX Oncology, Inc. was a drug development company focused predominantly on accelerated development of drugs for the treatment and prevention of cancer. The company used to offer drug development services on a contract basis to pharmaceutical and biotech companies through its ILEX Oncology Services subsidiary and used to advance a diversified portfolio of anticancer drugs through its ILEX Products subsidiary. It was located in San Antonio, TX. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2002 |
Cytokine Networks | Technik-/Wissenschafts-/F&E-Leiter | 01.01.1999 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 11 |
---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Pharmacyclics LLC
Pharmacyclics LLC Pharmaceuticals: MajorHealth Technology Pharmacyclics LLC engages in developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. It has product candidates in clinical development and several preclinical molecules in optimization. The company was founded by Jonathan Sessler and Richard Miller in 1991 and is headquartered in Sunnyvale, CA. | Health Technology |
CTI BioPharma Corp.
CTI BioPharma Corp. Pharmaceuticals: MajorHealth Technology CTI BioPharma Corp. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. It focuses on evaluating pacritinib, its sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA. | Health Technology |
ILEX Oncology, Inc.
ILEX Oncology, Inc. BiotechnologyHealth Technology ILEX Oncology, Inc. was a drug development company focused predominantly on accelerated development of drugs for the treatment and prevention of cancer. The company used to offer drug development services on a contract basis to pharmaceutical and biotech companies through its ILEX Oncology Services subsidiary and used to advance a diversified portfolio of anticancer drugs through its ILEX Products subsidiary. It was located in San Antonio, TX. | Health Technology |
Bridge Pharmaceuticals, Inc.
Bridge Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Bridge Laboratories is a preclinical contract research organization (CRO) that provides US-level regulatory-compliant drug development services globally. Bridge is known for its extensive work in toxicology, including vaccines, and safety pharmacology. The company's AAALAC-accredited facility in China was among the first labs to perform GLP studies for clients worldwide. Bridge Laboratories gives drug development clients-biotech/pharmaceutical firms, government agencies and virtual companies with strong outsourcing needs-a CRO choice that can dramatically improve the speed and cost-effectiveness of their drug development research programs. | Commercial Services |
SRI International
SRI International Miscellaneous Commercial ServicesCommercial Services SRI International provides contract research and development services. It is an independent, nonprofit research institute conducting client-sponsored research and development for government agencies, commercial businesses, foundations, and other organizations. The company was founded in 1946 and is headquartered in Menlo Park, CA. | Commercial Services |
Convergence Pharmaceuticals, Inc.
Convergence Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Convergence Pharmaceuticals, Inc. developed drugs to treat and prevent cancer. The company was headquartered in Boston, MA. | Health Technology |
EmergingMed.com, Inc.
EmergingMed.com, Inc. Medical/Nursing ServicesHealth Services EmergingMed.com, Inc. provides clinical trial services matching and referral services for cancer patients. It appropriate clinical trials and trial sites that match their specific diagnosis, stage, symptoms, and treatment history. The company was founded by Courtney Hudson in January 2000 and is headquartered in Durham, NC. | Health Services |
Critical Path Institute
Critical Path Institute Miscellaneous Commercial ServicesCommercial Services Critical Path Institute is a nonprofit organization established in 2005 as a public and private partnership with the FDA's Critical Path Initiative program. The non-profit company is based in Tucson, AZ, and operates from Ireland with additional staff in multiple other locations. The company's mission is to catalyze the development of new approaches that advance medical innovation and regulatory science, accelerating the path to a healthier world. The company orchestrates the development of drug development tools through an innovative, collaborative approach to the sharing of data and expertise, and accelerate the pace and reduce the costs of medical product development by building consensus among the participating institutions. The company was founded in 2005 by Raymond L. Woosley, Glenn C. Rice. Daniel M. Jorgensen has been the CEO of the company since 2022. | Commercial Services |
Cytokine Networks | |
Pacific Biopharma Group |